论文部分内容阅读
目的观察吉非替尼一线治疗晚期非小细胞肺癌临床疗效及毒副作用。方法研究2005年11月～2007年5月14例晚期非小细胞肺癌患者,PS≥2,一线口服吉非替尼治疗,250mg/日,观察其近期疗效及毒副作用。结果14例患者中CR 0%(0/ 14),PR 35.7%(5/14),SD 50%(7/14),PD 14.3%(2/14)。临床获益率85.7% (12/14)。毒副作用为唑疮样皮疹42.86%(6/14),皮肤干燥脱屑28.57%(4/14),皮肤瘙痒14.3%(2/14),腹泻35.7(5/14),转氨酶升高14.3%(2/14)。结论吉非替尼一线治疗晚期非小细胞肺癌疗效较好,毒副作用轻微,能明显改善患者的生活质量。
Objective To observe the clinical efficacy and side effects of gefitinib in the first-line treatment of advanced non-small cell lung cancer. Methods From November 2005 to May 2007, 14 patients with advanced non-small cell lung cancer (PS-2) were treated with gefitinib in the first-line therapy and 250 mg / day orally. The curative effect and toxicity were observed. Results Among the 14 patients, CR 0% (0/14), PR 35.7% (5/14), SD 50% (7/14) and PD 14.3% (2/14). The clinical benefit rate was 85.7% (12/14). Toxicity and side effects were 42.86% (6/14) for azole-like rash, 28.57% (4/14) for dry and desquamation, 14.3% (2/14) for itch, 35.7 (5/14) for diarrhea and 14.3% (2/14). Conclusion The first-line treatment with gefitinib in advanced non-small cell lung cancer has better curative effect and mild side effects, which can significantly improve the quality of life of patients.